Keita Kirito

Identification of myelodysplastic syndrome–specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction

Akira Miyazato, Shuichi Ueno, Ken Ohmine et al. · Blood · 2001 · 180 citations · Full text

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Srđan Verstovšek, A. M. Vannucchi, Tamás Masszi et al. · Haematologica · 2016 · 156 citations · Full text

Hematological Malignancy, Polycythemia Vera, Urology +15

A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction

Yoshifumi Kashii, Mie Uchida, Keita Kirito et al. · Blood · 2000 · 153 citations

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

Jean‐Jacques Kiladjian, Pierre Zachée, Masayuki Hino et al. · The Lancet Haematology · 2020 · 138 citations · Full text

Polycythaemia Vera, Medicine, Hematology +5

A Member of Forkhead Transcription Factor FKHRL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells

Norio Komatsu, Tomoko Watanabe, Mie Uchida et al. · Journal of Biological Chemistry · 2003 · 130 citations · Full text